Clinical Trials

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)



The purpose of this study is to investigate the safety and tolerability of topical SHP141 applied directly to skin lesions in patients with Stage IA, IB, or IIA Cutaneous T-cell Lymphoma. This study will also investigate the effect of SHP141 on skin lesions in patients with Stage IA, IB, or IIA CTCL.


Ages Eligible for Study:             18 years and older

Genders Eligible for Study:       Both

Accepts Healthy Volunteers:     No


  • Histopathologically confirmed CTCL; a documented verifiable biopsy report is required.
  • Documented clinical Stage IA, IB, or IIA CTCL.
  • Skin lesion involvement of at least 5% of BSA accessible for topical application of study drug and biopsy.
  • ECOG performance status of 0-2.


  • CTCL with histologic evidence of folliculotropic variant or large cell transformed CTCL.
  • Severe pruritus requiring systemic or topical treatment.
  • Palpable lymph node =1.5 cm in diameter (unless the lymph node has been biopsied and has been designated as Stage IA-IIA disease).
  • Coexistent second malignancy or history of prior solid organ malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix (CIN 3), papillary or follicular thyroid cancer that has been treated curatively, or prostate cancer that has been treated curatively).
  • Any prior history of a hematologic malignancy (other than CTCL).
  • History of or current major renal, hepatic, gastrointestinal, pulmonary, cardiovascular, genito-urinary or hematological disease, CNS disorders, infectious disease or coagulation disorders as determined by the Investigator.
  • Evidence of active Hepatitis B or C or HIV.
  • Circulating atypical cells >5%


Shape Pharmaceuticals, Inc.



Cleveland Clinic, Cleveland, OH
Amanda Maggiotto, 866.223.8100

English French German Italian Portuguese Russian Spanish

This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.